These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester.
    Author: Christiansen M, Nørgaard-Pedersen B.
    Journal: Clin Genet; 2005 Jul; 68(1):35-9. PubMed ID: 15952984.
    Abstract:
    Inhibin A is a maternal serum marker for fetal Down's syndrome (DS) in the second trimester. We examined whether inhibin A could be used early in the first trimester. Maternal serum concentrations of inhibin A were determined in 81 controls and 27 cases of fetal trisomy 21 in gestational week 5-11. The log MoM (Multiple of the Median of normal pregnancies) inhibin A concentration in DS pregnancies increased with gestational age (p = 0.001) from a mean log MoM (standard deviation) of -0.1754 (0.3712) (n = 11) in week 7-8 to a mean log MoM (standard deviation) of 0.1842 (0.2145) (n = 12) in week 9-11. This corresponded to an increase in inhibin median MoM from 0.67 to 1.53. When inhibin A was used together with pregnancy-associated plasma protein-A, free beta-human chorionic gonadotrophin and nuchal translucency as DS markers, the estimated detection rates were 81.4 and 82.6% in weeks 7-8 and 9-11, respectively, for false-positive rates of 0.9 and 1.0%. The performance of the latter combination early in the first trimester is nearly as good as that of integrated first- and second-trimester screening, with the further advantage that the risk can be reported to the pregnant woman in first trimester.
    [Abstract] [Full Text] [Related] [New Search]